Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9

Cell Reports

Volumn 17, Issue 5, 2016, Pages 1453-1461

  Gundry, Michael C ^a,b   Brunetti, Lorenzo ^a,b,c   Lin, Angelique ^a   Mayle, Allison E ^a,b   Kitano, Ayumi ^a   Wagner, Dimitrios ^b,d,e   Hsu, Joanne I ^a,b   Hoegenauer, Kevin A ^a   Rooney, Cliona M ^a,b,d   Goodell, Margaret A ^a,b,d   Nakada, Daisuke ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

^c UNIVERSITY OF PERUGIA   (Italy)

^d TEXAS CHILDREN S HOSPITAL   (United States)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CRISPR Cas9; gene therapy; genome editing; hematopoietic stem cells; homology directed repair; HSC; human CD34; progenitor; sgRNA; transplantation

Indexed keywords

CASPASE 9; CD34 ANTIGEN; CD45 ANTIGEN; DNA METHYLTRANSFERASE 3A; GREEN FLUORESCENT PROTEIN; RIBONUCLEOPROTEIN; RECEPTOR TYPE TYROSINE PROTEIN PHOSPHATASE C;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CELL DIVISION; CELL LOSS; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CRISPR CAS SYSTEM; DNMT3A GENE; EED GENE; GENE; GENE DISRUPTION; GENE FREQUENCY; GENE LOSS; GENE SEQUENCE; GENETIC PROCEDURES; GENOME EDITING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INDEL MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SUZ12 GENE; ANIMAL; DNA REPAIR; GENE DELETION; GENE EDITING; GENE INACTIVATION; GENETICS; METABOLISM; PROCEDURES;

ANIMALS; CRISPR-CAS SYSTEMS; DNA REPAIR; GENE DELETION; GENE EDITING; GENE KNOCKOUT TECHNIQUES; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKOCYTE COMMON ANTIGENS; MICE;

EID: 84994752276     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.09.092     Document Type: Article

References (31)

1. Brinkman, E.K., Chen, T., Amendola, M., van Steensel, B., Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res., 42, 2014, e168.
2. Chen, B., Gilbert, L.A., Cimini, B.A., Schnitzbauer, J., Zhang, W., Li, G.W., Park, J., Blackburn, E.H., Weissman, J.S., Qi, L.S., Huang, B., Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell 155 (2013), 1479–1491.
3. De Ravin, S.S., Reik, A., Liu, P.Q., Li, L., Wu, X., Su, L., Raley, C., Theobald, N., Choi, U., Song, A.H., et al. Targeted gene addition in human CD34(+) hematopoietic cells for correction of X-linked chronic granulomatous disease. Nat. Biotechnol. 34 (2016), 424–429.
4. Deneault, E., Cellot, S., Faubert, A., Laverdure, J.P., Fréchette, M., Chagraoui, J., Mayotte, N., Sauvageau, M., Ting, S.B., Sauvageau, G., A functional screen to identify novel effectors of hematopoietic stem cell activity. Cell 137 (2009), 369–379.
5. Genovese, P., Schiroli, G., Escobar, G., Di Tomaso, T., Firrito, C., Calabria, A., Moi, D., Mazzieri, R., Bonini, C., Holmes, M.C., et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 510 (2014), 235–240.
6. Goyama, S., Wunderlich, M., Mulloy, J.C., Xenograft models for normal and malignant stem cells. Blood 125 (2015), 2630–2640.
7. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M.P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C.S., Pawliuk, R., Morillon, E., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003), 415–419.
8. Heckl, D., Kowalczyk, M.S., Yudovich, D., Belizaire, R., Puram, R.V., McConkey, M.E., Thielke, A., Aster, J.C., Regev, A., Ebert, B.L., Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat. Biotechnol. 32 (2014), 941–946.
9. Hendel, A., Bak, R.O., Clark, J.T., Kennedy, A.B., Ryan, D.E., Roy, S., Steinfeld, I., Lunstad, B.D., Kaiser, R.J., Wilkens, A.B., et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33 (2015), 985–989.
10. Hoban, M.D., Cost, G.J., Mendel, M.C., Romero, Z., Kaufman, M.L., Joglekar, A.V., Ho, M., Lumaquin, D., Gray, D., Lill, G.R., et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood 125 (2015), 2597–2604.
11. Hope, K.J., Cellot, S., Ting, S.B., MacRae, T., Mayotte, N., Iscove, N.N., Sauvageau, G., An RNAi screen identifies Msi2 and Prox1 as having opposite roles in the regulation of hematopoietic stem cell activity. Cell Stem Cell 7 (2010), 101–113.
12. Hsu, P.D., Lander, E.S., Zhang, F., Development and applications of CRISPR-Cas9 for genome engineering. Cell 157 (2014), 1262–1278.
13. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., Charpentier, E., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337 (2012), 816–821.
14. Kim, S., Kim, D., Cho, S.W., Kim, J., Kim, J.S., Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 24 (2014), 1012–1019.
15. Konermann, S., Brigham, M.D., Trevino, A.E., Joung, J., Abudayyeh, O.O., Barcena, C., Hsu, P.D., Habib, N., Gootenberg, J.S., Nishimasu, H., et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517 (2015), 583–588.
16. Lee, S.C., Miller, S., Hyland, C., Kauppi, M., Lebois, M., Di Rago, L., Metcalf, D., Kinkel, S.A., Josefsson, E.C., Blewitt, M.E., et al. Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis. Blood 126 (2015), 167–175.
17. Li, D., Qiu, Z., Shao, Y., Chen, Y., Guan, Y., Liu, M., Li, Y., Gao, N., Wang, L., Lu, X., et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat. Biotechnol. 31 (2013), 681–683.
18. Lin, S., Staahl, B.T., Alla, R.K., Doudna, J.A., Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. eLife, 3, 2014, e04766.
19. Mandal, P.K., Ferreira, L.M., Collins, R., Meissner, T.B., Boutwell, C.L., Friesen, M., Vrbanac, V., Garrison, B.S., Stortchevoi, A., Bryder, D., et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 15 (2014), 643–652.
20. McDermott, S.P., Eppert, K., Lechman, E.R., Doedens, M., Dick, J.E., Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood 116 (2010), 193–200.
21. Moreno-Mateos, M.A., Vejnar, C.E., Beaudoin, J.D., Fernandez, J.P., Mis, E.K., Khokha, M.K., Giraldez, A.J., CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo. Nat. Methods 12 (2015), 982–988.
22. Platt, R.J., Chen, S., Zhou, Y., Yim, M.J., Swiech, L., Kempton, H.R., Dahlman, J.E., Parnas, O., Eisenhaure, T.M., Jovanovic, M., et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159 (2014), 440–455.
23. Qi, L.S., Larson, M.H., Gilbert, L.A., Doudna, J.A., Weissman, J.S., Arkin, A.P., Lim, W.A., Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152 (2013), 1173–1183.
24. Richardson, C.D., Ray, G.J., DeWitt, M.A., Curie, G.L., Corn, J.E., Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat. Biotechnol. 34 (2016), 339–344.
25. Rivière, I., Dunbar, C.E., Sadelain, M., Hematopoietic stem cell engineering at a crossroads. Blood 119 (2012), 1107–1116.
26. Rossi, L., Lin, K.K., Boles, N.C., Yang, L., King, K.Y., Jeong, M., Mayle, A., Goodell, M.A., Less is more: unveiling the functional core of hematopoietic stem cells through knockout mice. Cell Stem Cell 11 (2012), 302–317.
27. Schaefer, B.C., Schaefer, M.L., Kappler, J.W., Marrack, P., Kedl, R.M., Observation of antigen-dependent CD8+ T-cell/ dendritic cell interactions in vivo. Cell. Immunol. 214 (2001), 110–122.
28. Schumann, K., Lin, S., Boyer, E., Simeonov, D.R., Subramaniam, M., Gate, R.E., Haliburton, G.E., Ye, C.J., Bluestone, J.A., Doudna, J.A., Marson, A., Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc. Natl. Acad. Sci. USA 112 (2015), 10437–10442.
29. Shih, A.H., Abdel-Wahab, O., Patel, J.P., Levine, R.L., The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer 12 (2012), 599–612.
30. Sternberg, S.H., Doudna, J.A., Expanding the biologist's toolkit with CRISPR-Cas9. Mol. Cell 58 (2015), 568–574.
31. Xie, H., Xu, J., Hsu, J.H., Nguyen, M., Fujiwara, Y., Peng, C., Orkin, S.H., Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. Cell Stem Cell 14 (2014), 68–80.